A Study to Evaluate Oral VT-464 in Patients With Castration-Refractory Prostate Cancer
Read time: 1 mins
Last updated:6th Dec 2013
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-refractory prostate cancer (CRPC).
|Study start date||2013-12-06|